Cochrane · systematic review · CD010254
Rosuvastatin for lowering lipids
Adams, SP, Sekhon, SS, Wright, JM · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
HypertensionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 16.7%Low 1 · 16.7%Moderate 0 · 0%High 4 · 66.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
LDL‐cholesterol lowering efficacy of rosuvastatin for all trials
Population: participantswith normal or abnormal lipid profiles
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
LDL‐Cholesterol rosuvastatin 2.5 mg/day | no estimate extracted | 11 studies · 450 participants | Low Downgraded: risk of bias, imprecision, publication bias |
LDL‐Cholesterol rosuvastatin 5 mg/day | no estimate extracted | 25 studies · 2602 participants | High |
LDL‐Cholesterol rosuvastatin 10 mg/day | no estimate extracted | 74 studies · 9855 participants | High |
LDL‐Cholesterol rosuvastatin 20 mg/day | no estimate extracted | 28 studies · 3675 participants | High |
LDL‐Cholesterol rosuvastatin 40 mg/day | no estimate extracted | 18 studies · 3512 participants | High |
WDAE2 all doses | no estimate extracted | 10 studies · 1330 participants | Very low Downgraded: risk of bias, imprecision, publication bias |